Please use this identifier to cite or link to this item:
Title: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation: A Single Technology Appraisal. Evidence Review Group Report to NICE
Authors: Greenhalgh, J
Longworth, L
Crossan, C
Singh, J
Bagust, A
Beale, S
Richardson, M
Banks, L
Kotas, E
Hall, M
Keywords: Guidance;Edoxaban;Stroke;Prevention;Systemic embolism
Issue Date: 2015
Publisher: National Institute for Health and Care Excellence (NICE)
Citation: NICE technology appraisal guidance (TA355), (September 2015)
Abstract: 1.1 Edoxaban is recommended, within its marketing authorisation, as an option for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation with one or more risk factors, including: congestive heart failure hypertension diabetes prior stroke or transient ischaemic attack age 75 years or older
ISBN: 978-1-4731-1440-1
Appears in Collections:Health Economics Research Group (HERG)

Files in This Item:
File Description SizeFormat 
Fulltext.pdf232.75 kBAdobe PDFView/Open

Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.